| March 29, 2009 |
| Scientific breakthrough gives clues to treat Tylenol toxicity by targeting CD24 |
| OncoImmune's Co-founders, Drs. Yang Liu and Pan Zheng's laboratories at the University of Michigan, recently identified that the CD24 signaling is required for the immune system to distinguish the specific signaling from tissue damage vs. infection. The findings, released online March 5 and published on the current issue of Science, demonstrated that the association of CD24 and its co-receptor Siglec-10 (or its mouse homolog, Siglec-G) protects mice from lethal immune response induced by cellular injury but not infection. While the liver failure caused by cell damages from Tylenol and other drugs overdose is the most common drug-related toxicity and hospitalization in the United States. Please see the full story from UMHS Newsroom. (Full story) |
| |
| July 25, 2008 |
| OncoImmune receives SBIR Phase II competitive renewal award |
| OncoImmune announces the receiving of the SBIR Phase II competitive renewal grant award from National Institute of Health (NIH). The total award is $2.4 million to support OncoImmune's MS drug development program for the next 3 years. |
| |
| October 17, 2007 |
| OncoImmune opens Ann Arbor Laboratory |
| OncoImmune and Ann Arbor SPARK announce the opening of OncoImmune's new R&D in Ann Arbor, Michigan. OncoImmune is the first to occupy space in the new Business Technology Center, a wet-lab incubator created by University of Michigan and Ann Arbor SPARK to support life science startups. See the full story from the press release. (Full story) |
| |
| April 10, 2005 |
| OncoImmune receives $4.2 million BRTT grant |
| OncoImmune announces today that OncoImmune together with OSU and Cleveland Clinic received a $4.2 million BRTT grant. This grant will partially fund manufacturing and pre-clinical studies of its MS drug. See the exclusive report from the Business First-Columbus. (Full story) |
| |
| October 1, 2004 |
| Grant to help fuel more MS drug trials |
| OncoImmune announces the receiving of $860,000 federal grant (SBIR Phase II) to propel more development and commercialization of a molecular drug therapy for MS patients. See the exclusive report from the Business First-Columbus. (Full story) |
| |
| December 16, 2003 |
| Study links incidence of MS to gene |
| WIS News 10 reported the studies by Drs. Yang Liu and Pan Zheng, two co-founders of OncoImmune Inc. that a tiny difference on one gene could make a person twice as likely to develop Multiple Sclerosis, new research finds. (Full story) |